Format

Send to

Choose Destination
Cardiovasc Res. 2019 Feb 1;115(2):e12-e14. doi: 10.1093/cvr/cvy300.

Challenges and advances of CRISPR-Cas9 genome editing in therapeutics.

Author information

1
Cardiovascular Disease Prevention & Resilience Hub, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne, UK.
2
Department of Cardiology, Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
3
Division of Cardiology, Cardiovascular Institute, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
4
Department of Genetics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
PMID:
30668679
DOI:
10.1093/cvr/cvy300

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center